Given that CD44+CD117+ cells derived from the 2008 ovarian cancer cell line possess all CSC properties18, this result suggests that the ALDH1A1 inhibitor is also able to inhibit the ovarian cancer cell dedifferentiation. This evidence concerns the gene ALDH1A1 and ovarian carcinoma.